• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Vaccine Investment Strategy: report from an expert survey

tetano

Editor, Senior Moderator
F1000Res. 2019 Sep 24;8:1685. doi: 10.12688/f1000research.20100.1. eCollection 2019. [h=1]Vaccine impact on antimicrobial resistance to inform Gavi, the Vaccine Alliance's 2018 Vaccine Investment Strategy: report from an expert survey.[/h]
Malarski M[SUP]1[/SUP], Hasso-Agopsowicz M[SUP]2[/SUP], Soble A[SUP]3[/SUP], Mok W[SUP]1[/SUP], Mathewson S[SUP]1[/SUP], Vekemans J[SUP]2[/SUP].
[h=3]Author information[/h] 1 Policy, Vaccines & Sustainability, Gavi, the Vaccine Alliance, Le Grand-Saconnex, 1218, Switzerland. 2 Immunization, Vaccines, and Biologicals, World Health Organization, Geneva, 1211, Switzerland. 3 Vaccine Supply & Demand, Vaccines & Sustainability, Gavi, the Vaccine Alliance, Le Grand-Saconnex, 1218, Switzerland.

[h=3]Abstract[/h] Background: While the rise of antimicrobial resistance (AMR) has been recognised as a major public health problem, the value of vaccines to control AMR is poorly defined. This expert survey was launched with the aim of informing the 2018 Vaccine Investment Strategy through which Gavi, the Vaccine Alliance prioritises future vaccine funding. This exercise focused on both vaccines currently supported by Gavi and under consideration for future funding. Methods: The relative importance of pre-defined criteria as drivers of overall value of vaccines as a tool/ intervention to control AMR was assessed by 18 experts: prevention of mortality and morbidity due to resistant pathogens, antibiotic use prevented, societal impact, ethical importance and sense of urgency. For each vaccine, experts attributed scores reflecting the estimated value for each criterion, and overall value relative to AMR was derived from the value assigned to each criterion and their relative importance for each vaccine. Results: Mortality, morbidity due to targeted resistant pathogens, and antibiotic use prevented were considered the most important determinants of overall value. Pneumococcal, typhoid and malaria vaccines were assigned highest value relative to antimicrobial resistance. Intermediate value was estimated for specific rotavirus, cholera, respiratory syncytial virus (RSV), influenza, dengue, measles, meningitis and Haemophilus influenza type b- (Hib-) containing pentavalent vaccines. Lowest value relative to AMR was estimated for Japanese encephalitis, hepatitis A, yellow fever, rabies and human papilloma virus vaccine. Conclusions: In the future, more evidence-based, data-driven, robust methodologies should be developed to guide coordinated, rational decision making on priority actions aimed at strengthening the use of vaccines against AMR.
Copyright: ? 2019 Malarski M et al.


[h=4]KEYWORDS:[/h] Vaccines; antimicrobial resistance

PMID: 31737260 PMCID: PMC6807152 DOI: 10.12688/f1000research.20100.1
Free full text
 
Back
Top Bottom